PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice
Authors:
- Kiyoshi MoriKMKiyoshi Mori
- Masashi MukoyamaMMMasashi Mukoyama
- Kazuwa NakaoKNKazuwa Nakao
- 1 June 2011
- journal article
- editorial
- Published by Elsevier in Kidney International
- Vol. 79 (12) , 1274-1276
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injuryKidney International, 2011
- Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in miceJournal of Clinical Investigation, 2010
- PPARα: an emerging therapeutic target in diabetic microvascular damageNature Reviews Endocrinology, 2010
- Transgenic expression of proximal tubule peroxisome proliferator–activated receptor-α in mice confers protection during acute kidney injuryKidney International, 2009
- Peroxisomal Proliferator-Activated Receptor-α Protects Renal Tubular Cells from Doxorubicin-Induced ApoptosisMolecular Pharmacology, 2007
- The podocyte's response to injury: Role in proteinuria and glomerulosclerosisKidney International, 2006
- PPARα agonist fenofibrate improves diabetic nephropathy in db/db miceKidney International, 2006
- Accelerated Diabetic Nephropathy in Mice Lacking the Peroxisome Proliferator–Activated Receptor αDiabetes, 2006
- Involvement of PPAR nuclear receptors in tissue injury and wound repairJournal of Clinical Investigation, 2006
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 2005